The CSNK1G1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-mediated polyclonal knockout cell population with disruption of the CSNK1G1 gene in the Raji B lymphocyte line. This polyclonal format provides a heterogeneous pool of gene-edited cells, enabling robust loss-of-function analysis without single-cell cloning. The model is particularly suited for investigating CSNK1G1-dependent signaling processes in a B cell context.
Raji is a suspension-adapted lymphoblastoid cell line derived from a Burkitt lymphoma patient and is latently infected with Epstein-Barr virus (EBV). These B lymphocytes exhibit key adaptive immune functions, including antibody secretion and antigen presentation, and serve as a standard model for B cell malignancies and EBV-associated lymphomagenesis.
CSNK1G1 encodes a serine/threonine kinase that functions centrally in the canonical Wnt/??-catenin pathway. Upon Wnt stimulation (e.g., WNT3A, WNT1) through Frizzled receptors and LRP5/6 coreceptors, it phosphorylates dishevelled proteins (DVL1?C3) and LRP6, leading to ??-catenin stabilization and nuclear translocation. There, ??-catenin partners with TCF/LEF factors to drive transcription of target genes such as MYC and CCND1. Additional roles include circadian clock regulation via PER2 phosphorylation and modulation of cell cycle progression. CSNK1G1 interacts with AXIN1, APC, and GSK3??, integrating its activity within the destruction complex.
In Raji B lymphocytes, CSNK1G1 knockout enables dissection of Wnt pathway contributions to lymphomagenesis. As Raji is derived from Burkitt lymphoma, often associated with aberrant Wnt signaling, this model reveals kinase-dependent effects on proliferation and survival. The polyclonal population maintains tumor heterogeneity, supporting realistic drug response studies. EBV positivity further allows investigation of viral-host kinase interactions.
Typical research applications include functional genomics of kinase signaling networks, high-throughput drug screening for Wnt pathway inhibitors, and mechanistic studies of B cell malignancies. Researchers can employ western blotting to assess ??-catenin and phospho-LRP6 levels, RT-qPCR for target genes (MYC, CCND1), TopFlash luciferase reporter assays for TCF/LEF activity, flow cytometry for the B cell markers CD19 and CD20, co-immunoprecipitation to probe CSNK1G1-DVL interactions, apoptosis detection by annexin V staining, and RNA-seq for transcriptome-wide profiling. For detailed technical guidance or to request a custom solution, please contact Ascent Research.
